Ltr Pharma Limited · ASX:LTP
Ltr Pharma — Shareholder Meeting (October 2025)
16 slides from Ltr Pharma's shareholder meeting presentation, Oct 24, 2025
Slide 1: 2025 Annual General Meeting Presentation
2025 Annual General Meeting Presentation 24 October 2025 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the “Company”) advises that the Annual General Meeting (“AGM”) will be held today, Friday, 24 October 2025, at 2:00pm (AEST), at the offices of K&L Gates 16/66 Eagle Street, Brisbane City QLD 4000
Slide 2: Annual General Meeting
For personal use only Annual General Meeting 24 October 2025 AGM Presentation | October 2025
Slide 3: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only Investor Presentation 2
Slide 4: A transformative year of clinical and commercial success
A transformative year of clinical and commercial success For personal use only Australian Financial Year Q1 2024/25 Q2 2024/25 Q3 2024/25 Q4 2024/25 Q1 2025/26 SPONTAN Online JV Platform ROXUS OROFLOW US-based ED prescribed to first launch Development agreement signed specialists join patient under
Slide 5: Investment Highlights
Investment Highlights LTR Pharma positioned in a clear gap in the market For personal use only Diversified Compelling pivotal Blockbuster market Blue chip Multiple upcoming Commercial Strategy pharmacokinetic with issues partners milestones Reducing Risk study data ‣ SPONTAN® active ‣ 5x faster abso
Slide 6: Understanding the Market Need
Understanding Psychological Impact Physical causes the Market Need ‣ Heart Health ‣ Relationship problems For personal use only ‣ Mental Wellbeing A significant healthcare ‣ Prostate Health ‣ Day to day stress challenge affecting ‣ Diabetes relationships and ‣ Medical Treatments quality of life ‣ Ha
Slide 7: Global Market Need
Global Market Need ED can impact physical and psychological health For personal use only USA China Aus EU 60.7% ~30m ~33m ~150m of males 45y/o+ Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023 AGM Presentation 6
Slide 8: Estimated Market size
Estimated Market size Forecast to be US$6.0B market by 2028 For personal use only US$6.0B US$5.0B 7.0% CAGR US$4.0B $4.15B $3.87B US$ billions $3.61B US$3.0B $3.38B $3.16B $2.95B $2.76B $2.58B US$2.0B US$1.0B $1.56B $1.67B $1.79B $1.18B $1.27B $1.36B $1.45B $1.11B US$0.0B 2021 2022 2023F 2024F 2025F
Slide 9: Current Treatments
Current Treatments Oral PDE5 inhibitors & SPONTAN® Nasal Spray For personal use only Oral Phosphodiesterase-5 (PDE5) Issues with oral inhibitors are first-line treatments PDE5 inhibitors Product Main Time before sexual Approval Generic Does not work Brand(s) activity for dose Date (US) availability
Slide 10: SPONTAN: The Science of Superior Delivery
SPONTAN® The Science of Superior Delivery Faster and More Potent For personal use only Speed Superiority Healthcare Professional Insight ‣ Tmax: 5 x faster than oral tablets Patients can respond in as little as 5 minutes, ‣ Peak concentration in as little as 9 mins well before peak concentration is
Slide 11: Making headlines in FY25
Making headlines in FY25 For personal use only Throughout FY25, LTR Pharma maintained a strong media presence across Ausbiz, The Australian, The West Australian, and Medical Forum, reinforcing SPONTAN awareness and commercial progress. The Company's Conversation Series expanded with expert-led conte
Slide 12: Company History
Company History Progressed company substantially derisking the proposition For personal use only 2020 - 2021> 2022 > Acquired exclusive worldwide rights Establishment of the Validated the US FDA’s 505(b)(2) Optimised delivery and commercial to develop, manufacture and market SPONTAN® Scientific Advi
Slide 13: Board of Directors
Board of Directors Seasoned leadership driving innovation and growth in healthcare For personal use only Mr. LEE RODNE Ms. MAJA MCGUIRE Dr. JULIAN CHICK (Executive Chairman) (Independent Non-Executive Director) (Independent Non-Executive Director) ▲ 25 years in healthcare and tech ▲ 15 years of expe
Slide 14: Global Team, Strategic US Presence
Global Team, Strategic US Presence Experienced leadership across key markets For personal use only Executive Chairman | Lee Rodne General Manager & Business Development US |Tom Riester 25 years in healthcare and tech sectors in both public ASX and private enterprises. 25 years experience in sales an
Slide 15: Key Milestones 2025-2026
2025-2026 Key Milestones For personal use only Calendar Year Q4 2025 Q1 2026 H1 2026 2026 Additional Activities Animal Tox study Phase II enrolment ROXUS 1st US Sales Published data commencement Phase II completion and data PK study enrolment Partnerships discussions read out Human factor study TGA
Slide 16: Corporate Structure
Corporate Structure For personal use only ASX Code LTP Shares on issue 181.61M Market Capitalisation A$96M Cash and cash equivalents (30 June 2025) A$31.84M Top 20 shareholder percentage 43.25% As of 23 October 2025 AGM Presentation 15